Apomorphine Effects on Experimental Pain
Overview
The aims of this study were to assess the effects of the dopamine agonist apomorphine on experimental pain models in healthy subjects and to explore the possible association between these effects and a common polymorphism within the dopamine transporter gene.
Full Title of Study: “Alterations in the Ability to Tolerate Experimental Pain by Apomorphine and Its Association With a Dopamine Transporter Polymorphism”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Primary Purpose: Basic Science
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Study Primary Completion Date: July 2011
Detailed Description
Healthy volunteers (n=105) participated in this randomized double-blind, placebo-controlled, cross-over trial. Heat pain threshold and intensity, cold pain threshold, and the response to tonic cold pain (latency, intensity, and tolerance) were evaluated before and for up to 120 min after the administration of 1.5 mg apomorphine/placebo. A polymorphism (DAT-1) within the dopamine transporter gene (SLC6A3) was investigated.
Interventions
- Drug: Apomorphine
- 1.5 mg Apomorphine
Arms, Groups and Cohorts
- Placebo Comparator: Saline
- Assessment of experimental pain models before and after treatment
- Active Comparator: Apomorphine
- Assessment of experimental pain models before and after treatment
Clinical Trial Outcome Measures
Primary Measures
- Cold pain tolerance
- Time Frame: 120 minutes
Participating in This Clinical Trial
Inclusion Criteria
- healthy and free from chronic pain of any type did not use any medications other than oral contraceptives were able to understand the purpose and instructions of the study.
Exclusion Criteria
- any type of medical or painful condition use of medications or recreational drugs pregnancy.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 40 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- Rambam Health Care Campus
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Elon Eisenberg, MD, Principal Investigator, Rambam Health Care Campus, Haifa, Israel
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.